The global single-photon emission computed tomography market has shown remarkable growth, achieving a valuation of USD 2.28 billion in 2021. According to recent market research, this figure is expected to rise to USD 2.45 billion by the end of 2022, driven by the increasing prevalence of cardiovascular diseases and the growing demand for advanced diagnostic technologies. The market is poised for an impressive 6.9% compound annual growth rate (CAGR) from 2022 to 2032, potentially reaching USD 4.76 billion by 2032.
The single imaging gamma cameras segment led the global SPECT market in 2021, commanding a substantial market share of approximately 75.5%. This segment is anticipated to maintain its dominance throughout the forecast period, showcasing the critical role of gamma cameras in the efficacy of SPECT imaging.
SPECT is a cutting-edge nuclear medicine technique that produces three-dimensional images of functional processes within the human body. By utilizing short-lived radioisotopes, SPECT enables non-invasive diagnostic imaging of metabolic processes, making it a crucial tool for detecting chronic illnesses and assessing cellular and organ function in relation to disease processes.
In recent years, the advancement of nuclear imaging apparatus, including SPECT imaging systems, has underscored the importance of enhancing diagnostic capabilities, particularly in organic-specific or dual-modality systems. This evolution in technology is expected to significantly contribute to market expansion in the coming decade.
As the healthcare sector continues to prioritize innovative diagnostic solutions, SPECT is well-positioned to meet the rising demand for accurate and efficient imaging techniques. With its ability to provide detailed metabolic and functional insights, SPECT is set to play an increasingly vital role in the diagnosis and management of various diseases.
Key Takeaways: Single-Photon Emission Computed Tomography (SPECT) Market
- The global SPECT market reached USD 2.28 billion in 2021 and is expected to reach USD 2.45 billion by 2022.
- The market is expected to grow at a CAGR of 6.9% from 2022 to 2032, reaching a valuation of USD 4.76 billion by 2032. This growth is attributed to the rising prevalence of cardiovascular diseases and the demand for better diagnostic tools.
- North America, with the USA holding a dominant 38% share in 2021, is expected to continue leading the market due to favorable reimbursement policies for nuclear medicine procedures.
- China’s SPECT market, with a 5.3% share in 2021, is projected for healthy growth due to advancements in medical infrastructure, focus on chronic disease management, and government support for cancer research.
- Germany, with an aging population and increasing use of radiopharmaceutical diagnostics, is expected to hold a nearly 5% market share due to government funding initiatives.
Stay Ahead with Single-Photon Emission Computed Tomography: Delve into Our Full Report for Extensive Trends and Insights!
Competitive Landscape:
Major players in the single-photon emission computed tomography (SPECT) market are aggressively pursuing market dominance through strategic partnerships, product launches, and expansion efforts. For example:
- In November 2020, GE Healthcare acquired Prismatic Sensors AB, a Swedish startup known for its expertise in photon-counting detectors. This acquisition underscores GE Healthcare’s ongoing commitment to advancing photon-counting CT technology.
- In May 2022, Mediso Ltd. acquired Bartec Technologies Ltd., a UK-based company specializing in the supply, installation, and support of Nuclear Medicine and Molecular Imaging equipment and accessories.
These moves highlight the proactive strategies employed by industry leaders to strengthen their positions and drive innovation in the SPECT market.
Key Companies Profiled:
- Bruker Corp.
- DDD-Diagnostic AS
- Digmed Corp.
- General Electric Co.
- Mediso Ltd.
- MiE GmbH
- MILabs BV
- Siemens Healthineers AG
- Spectrum Dynamics Medical Inc.
- GE Healthcare
- CardiArc
- Beijing Hamamatsu Photon Techniques INC.
- SHENZHEN BASDA MEDICAL APPARATUS CO., LTD.
- PNPMed
- NuCare Inc.
Key Market Segments Covered in Single-photon Emission Computed Tomography Industry Research:
By Product:
- Single Imaging Gamma Cameras
- SPECT/CT
By Application:
- Cardiology
- Oncology
- Neurology
- Others
By End User:
- Hospitals
- Diagnostic Imaging Centers
- Ambulatory Surgical Centers
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa(MEA)
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
